Trading Statement

RNS Number:9095R
Celsis International PLC
29 September 2005


                            CELSIS INTERNATIONAL PLC

                            Pre-close Trading Update


29 September 2005: Celsis International plc, the rapid microbial detection and
analytical services company, today announces an update on trading prior to the
commencement of its close period.

Celsis has made good progress in the first half of the year and as a result the
company is on track to perform in line with the Board's expectations for the six
months to 30 September 2005.

The Product Group division continues to achieve good growth with the Laboratory
Group maintaining its last year second half performance following a slight
impact from a slow down in pharmaceutical companies spending.  Overall the
company has seen robust trading during this financial period, especially
compared to the extremely strong first half year results in 2004.

Jay LeCoque, Chief Executive Officer, Celsis International plc commented:

"I am pleased to report that Celsis has performed well during the first half of
this financial year and I look forward to a successful second half.

Our recent agreement with BioVentures to develop microarray and other rapid
microbial detection systems demonstrates Celsis' commitment to remaining the
world leader in our field.  These new technologies will enable Celsis to
significantly expand its business both in existing as well as future new
markets.

Celsis' strong cash position means the company is well placed for future growth
and I remain confident about the company's prospects."

Celsis will announce its interim results for the six months to 30 September
2005, on Tuesday 8 November 2005.  There will be a presentation to analysts on
the day at 9.30am, held at Financial Dynamics, Holborn Gate, 26 Southampton
Buildings, London, WC2A 1PB.


Enquiries:

Celsis International plc                                      Tel: [phone]
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications

Financial Dynamics                                            Tel: [phone]
Ben Atwell


Notes to editors

Celsis International plc

Celsis International plc is a rapid microbial detection and analytical services
company operating through two divisions, the Product Group and the Laboratory
Group.

Using its proprietary enzyme technology, the Product Group is the world leader
in the provision of diagnostic systems for the rapid detection of microbial
contamination.  It works in close collaboration with many of the world's leading
pharmaceutical, personal care and beverage companies, ensuring the safety and
quality of products bound for consumers.  The Laboratory Group provides
outsourced analytical testing services to pharmaceutical and biopharmaceutical
companies to ensure the stability and chemical composition of their products.

In addition to ensuring product quality and safety for consumers, both divisions
have the capacity to deliver substantial cost savings to Celsis' customers.  By
reducing the time it takes to test and release raw materials and finished goods
to the market place, Celsis' products facilitate increased manufacturing
productivity and improved supply chain management.

Celsis International plc is listed on the London Stock Exchange (CEL.L).
Further information can be found on the Company's website at www.celsis.com.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

TSTGGGZLNRVGKZM